Published in Cancer on September 09, 2010
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.12
microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One (2012) 1.11
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol (2013) 1.02
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal (2013) 0.92
Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. BMC Cancer (2012) 0.89
Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther (2013) 0.89
Targeted therapy for renal cell carcinoma: The next lap. J Carcinog (2014) 0.89
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer (2012) 0.88
Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin (2011) 0.86
P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death Dis (2014) 0.86
Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep (2014) 0.81
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol (2013) 0.81
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest (2016) 0.76
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
mTORC2 controls cancer cell survival by modulating gluconeogenesis. Cell Death Discov (2015) 0.75
Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Clin Cancer Res (2014) 0.75
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol (2016) 0.75
MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells. J Biol Chem (2016) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol (2002) 3.52
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol (2010) 3.20
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology (2010) 2.99
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer (2010) 2.75
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol (2008) 2.45
Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Hum Mol Genet (2002) 2.33
Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol (2005) 2.32
Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25
Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J (2004) 2.18
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol (2002) 2.15
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet (2003) 1.97
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer (2002) 1.81
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer (2012) 1.70
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol (2007) 1.65
Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology (2006) 1.63
Marrow stromal cells as universal donor cells for myocardial regenerative therapy: their unique immune tolerance. Ann Thorac Surg (2008) 1.62
Mesenchymal neoplasms of the kidney in adults: imaging spectrum with radiologic-pathologic correlation. Radiographics (2010) 1.62
Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol (2007) 1.59
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol (2009) 1.55
Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int (2007) 1.54
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol (2010) 1.52
Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol (2007) 1.52
Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int (2012) 1.51
Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis (2010) 1.50
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol (2011) 1.49
Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases. Hum Pathol (2011) 1.48
Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. Urology (2004) 1.47
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec. Can Urol Assoc J (2008) 1.45
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians. BJU Int (2010) 1.41
The unsuspected nonpalpable testicular mass detected by ultrasound: a management problem. Can J Urol (2003) 1.39
Incorporation of the da Vinci Surgical Skills Simulator at urology Objective Structured Clinical Examinations (OSCEs): a pilot study. Can J Urol (2016) 1.39
Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol (2008) 1.35
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer (2009) 1.33
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology (2003) 1.33
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One (2012) 1.30
A role for Brca1 in chromosome end maintenance. Hum Mol Genet (2006) 1.29
Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney. Arch Pathol Lab Med (2008) 1.28
Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev (2009) 1.27
Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol (2006) 1.26
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol (2009) 1.25
Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol (2010) 1.24
Intraluminal polypoid metastasis of renal cell carcinoma in gallbladder mimicking gallbladder polyp. Arch Pathol Lab Med (2010) 1.22
The use of whole genome amplification in the study of human disease. Prog Biophys Mol Biol (2005) 1.22
Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract (2013) 1.21
Downstream divergence of the ethylene signaling pathway for harpin-stimulated Arabidopsis growth and insect defense. Plant Physiol (2004) 1.21
Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med (2002) 1.20
Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer (2007) 1.20
Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol (2010) 1.19
Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J (2007) 1.19
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer (2010) 1.19
Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol (2011) 1.18
Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev (2004) 1.18
Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res (2009) 1.17
Murine Pif1 interacts with telomerase and is dispensable for telomere function in vivo. Mol Cell Biol (2006) 1.16
Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol (2013) 1.15
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene (2003) 1.15
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses (2013) 1.15
Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. J Clin Pathol (2007) 1.14
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (2010) 1.14
Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer (2010) 1.13
Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol (2009) 1.13
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res (2009) 1.13
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol (2003) 1.13
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol (2011) 1.13
Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. Cancer Genet Cytogenet (2009) 1.12
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer (2003) 1.12
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer (2011) 1.11
Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system. Can Urol Assoc J (2011) 1.11
Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene (2003) 1.11
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol (2002) 1.11